Opus Genetics, Inc. Stock 12‑Month Price Target Raised to $10.69, Implies 163% Upside

Opus Genetics, Inc.'s average 12-month price target was raised to $10.69 by 16 analysts, up from $10.59. Based on the June 17 closing price, this implies a 163% upside potential. The consensus rating remains 'Buy' with no Holds or Sells.

According to estimates from 16 analysts, Opus Genetics, Inc. stock's average price target has risen from $10.59 to $10.69, with forecasts ranging from $8 to $16 per share
Based on the Jun. 17 closing price, the updated target implies approximately 163% potential upside
Consensus rating remains at “Buy” across 16 covering analysts, with 16 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Opus Genetics, Inc. on the , and track all previous and future analyst recommendations for Opus Genetics, Inc. in the dedicated News Flow.

Disclaimer

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.